Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stress
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
In sickle cell disease, nitric oxide (NO) depletion by cell-free plasma hemoglobin and/or oxygen radicals is associated with arginine deficiency, impaired NO bioavailability, and chronic oxidative stress. In transgenic-knockout sickle (BERK) mice that express exclusively human α- and β S-globins, reduced NO bioavailability is associated with induction of non-NO vasodilator enzyme, cyclooxygenase (COX)-2, and impaired NO-mediated vascular reactivity. We hypothesized that enhanced NO bioavailability in sickle mice will abate activity of non-NO vasodilators, improve vascular reactivity, decrease hemolysis, and reduce oxidative stress. Arginine treatment of BERK mice (5% arginine in mouse chow for 15 days) significantly reduced expression of non-NO vasodilators COX-2 and heme oxygenase-1. The decreased COX-2 expression resulted in reduced prostaglandin E 2(PGE 2) levels. The reduced expression of non-NO vasodilators was associated with significantly decreased arteriolar dilation and markedly improved NO-mediated vascular reactivity. Arginine markedly decreased hemolysis and oxidative stress and enhanced NO bioavailability. Importantly, arteriolar diameter response to a NO donor (sodium nitroprusside) was strongly correlated with hemolytic rate (and nitrotyrosine formation), suggesting that the improved microvascular function was a response to reduced hemolysis. These results provide a strong rationale for therapeutic use of arginine in sickle cell disease and other hemolytic diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease
Reiter, C. D., Wang, X., Tanus-Santos, J. E., Hogg, N., Cannon, R. O., Schechter, A. N., & Gladwin, M. T. (2002) · Nature Medicine · doi:10.1038/nm1202-799 · Cited by 1,330 · cited 5×
“An important finding of the present studies with implications for NO bioavailability is the pronounced 50% decrease in cell-free plasma hemoglobin in arginine-treated BERK mice (see Table 1), which is expected to reduce NO inactivation by cell-free ferrous (oxy) hemoglobin (36).”
BackgroundInfluentialZou, M.-H., Shi, C., & Cohen, R. A. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0214442 · Cited by 494
Transgenic Knockout Mice with Exclusively Human Sickle Hemoglobin and Sickle Cell Disease
Pászty, C., Brion, C. M., Manci, E., Witkowska, H. E., Stevens, M. E., Mohandas, N., & Rubin, E. M. (1997) · Science · doi:10.1126/science.278.5339.876 · Cited by 467
Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease
Aslan, M., Ryan, T. M., Adler, B., Townes, T. M., Parks, D. A., Thompson, J. A., Tousson, A., Gladwin, M. T., Patel, R. P., Tarpey, M. M., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.221292098 · Cited by 391 · cited 4×
“SCD is characterized by hemolytic anemia and reperfusion injury (excessive oxidant generation), both of which contribute to NO consumption and/or inactivation (1, 16, 18, 31, 36).”
BackgroundInfluentialHsu, L. L., Champion, H. C., Campbell-Lee, S. A., Bivalacqua, T. J., Manci, E. A., Diwan, B. A., Schimel, D. M., Cochard, A. E., Wang, X., Schechter, A. N., et al. (2007) · Blood · doi:10.1182/blood-2006-08-039438 · Cited by 263
The Perfusion Paradox and Vascular Instability in Sickle Cell Disease
NATH, K. A., KATUSIC, Z. S., & GLADWIN, M. T. (2004) · Microcirculation · doi:10.1080/10739680490278592 · Cited by 102 · cited 10×
“These results provide a strong rationale for therapeutic use of arginine in sickle cell disease and other hemolytic diseases. sickle cell disease; microvascular regulation; vasoreactivity ACCUMULATING EVIDENCE SHOWS reduced bioavailability of nitric oxide (NO) in human sickle cell disease (SCD) and transgenicknockout…”
BackgroundInfluential
Cited by
Arginine metabolism and nutrition in growth, health and disease
Wu, G., Bazer, F. W., Davis, T. A., Kim, S. W., Li, P., Marc Rhoads, J., Carey Satterfield, M., Smith, S. B., Spencer, T. E., & Yin, Y. (2009) · Amino Acids · doi:10.1007/s00726-008-0210-y · Cited by 1,362
Wijnands, K. A. P., Vink, H., Briedé, J. J., van Faassen, E. E., Lamers, W. H., Buurman, W. A., & Poeze, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037439 · Cited by 136
“[1–3], which makes organ perfusion an important therapeutic target [4,5].”
BackgroundBrain neurochemical and hemodynamic findings in the NY1DD mouse model of mild sickle cell disease
Cui, M., Suzuka, S. M., Branch, N. A., Ambadipudi, K., Thangaswamy, S., Acharya, S. A., Billett, H. H., & Branch, C. A. (2017) · NMR in Biomedicine · doi:10.1002/nbm.3692 · Cited by 11
Metadata
- Authors
- Kaul, D. K., Zhang, X., Dasgupta, T., & Fabry, M. E.
- Venue
- American Journal of Physiology-Heart and Circulatory Physiology
- Publisher
- American Physiological Society
- Published
- 2008-07
- Volume
- 295
- Issue
- 1
- Pages
- H39-H47
- ISSN
- 0363-6135 (ISSN-L)
- 1522-1539
- OpenAlex
- W2084540644
- Cited by
- 80
- References
- 6
- FWCI
- 3.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stress. https://app.cochat.ai/papers/10.1152/ajpheart.00162.2008
- The paper
- Kaul, D. K., Zhang, X., Dasgupta, T., & Fabry, M. E. (2008). Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stress. American Journal of Physiology-Heart and Circulatory Physiology. https://doi.org/10.1152/ajpheart.00162.2008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.